RxDoctor Payments Data

Erica Muniz

Family · Wellington, FLNPI 1578236196

Payments from drug & device makers

$5,706in general payments, 2019–2025

Across 294 payments — averaging $19.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$857
  • Sanofi-aventis U.S. LLC$676
  • Novo Nordisk$660
  • Medtronic$641
  • Xeris Pharmaceuticals, Inc.$588
  • AbbVie$404
  • plus $2K from 27 others

What the payments were for

  • Travel & lodging$3937%
  • Food & beverage$5,28993%
  • Education$240%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,706 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide98$157,152
OzempicSemaglutide88$136,881
JardianceEmpagliflozin38$59,469
JanuviaSitagliptin Phosphate48$48,672
Tresiba Flextouch U-100Insulin Degludec29$29,271
TrulicityDulaglutide21$25,411
Humulin R U-500 KwikpenInsulin Regular, Human15$16,398
Fiasp FlextouchInsulin Aspart (Niacinamide)17$12,302
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog15$11,843
Lyumjev Kwikpen U-100Insulin Lispro-Aabc12$11,583
Tresiba Flextouch U-200Insulin Degludec12$10,837
Novolog FlexpenInsulin Aspart14$5,796
SynthroidLevothyroxine Sodium40$4,833
Nano 2nd Gen Pen NeedlePen Needle, Diabetic33$4,615
Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm12$3,664

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$857$182,563119 claims
Novo NordiskOzempic$660$136,88188 claims
Boehringer IngelheimJardiance$192$59,46938 claims
MerckJanuvia$15$48,67248 claims
AbbVieSynthroid$404$4,83340 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$137$1,397123 claims
Acella Pharmaceuticals, LLCNp Thyroid$35$42411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.

Other family in Wellington

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →